Bioatla presented data characterizing mutated kras genotype and clinical outcomes in patients with advanced nsclc treated with mecbotamab vedotin (mec-v), a cab-axl-adc, at the iaslc 2024 hot topic in basic & translational science meeting

Improved median overall survival (os) for mec-v treated patients with treatment-refractory non-small cell lung cancer (nsclc) expressing mutated kras (mkras) as compared to mec-v treated patient with treatment-refractory nsclc expressing wild-type kras (wtkras)
BCAB Ratings Summary
BCAB Quant Ranking